You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

港股異動 | 康寧傑瑞製藥-B漲超6% 新藥臨牀試驗申請獲批准

格隆匯 11-25 14:19
格隆匯11月25日丨康寧傑瑞製藥-B(9966.HK)漲6.42%，報19.9港元，總市值186億港元。

公司KN046治療晚期PDAC的III期臨牀試驗日前獲國家藥監局IND批准，KN046-303是一項對未接受系統性治療的不可切除局部晚期或轉移性PDAC患者進行的，公司相信KN046有潛力被開發為突破性腫瘤免疫特效藥。

據悉，集團已發佈KN046在治療既往免疫檢查點抑制劑治療失敗患者的初步及良好安全性和療效數據。

康宁杰瑞制药-B(09966.HK)
20240513康宁杰瑞制药-B09966
Relevant Stocks
康宁杰瑞制药-B(09966.HK)
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.